MX2024000908A - Metodo para producir derivado de arilamida. - Google Patents

Metodo para producir derivado de arilamida.

Info

Publication number
MX2024000908A
MX2024000908A MX2024000908A MX2024000908A MX2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A MX 2024000908 A MX2024000908 A MX 2024000908A
Authority
MX
Mexico
Prior art keywords
arylamide derivative
fluoropyridin
amino
pharmaceutically acceptable
making
Prior art date
Application number
MX2024000908A
Other languages
English (en)
Spanish (es)
Inventor
Kazuaki KUWATA
Hidehisa SOMEYA
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2024000908A publication Critical patent/MX2024000908A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00Other general methods
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024000908A 2021-07-21 2022-07-20 Metodo para producir derivado de arilamida. MX2024000908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021120977 2021-07-21
PCT/JP2022/028187 WO2023003014A1 (ja) 2021-07-21 2022-07-20 アリールアミド誘導体の製造方法

Publications (1)

Publication Number Publication Date
MX2024000908A true MX2024000908A (es) 2024-02-07

Family

ID=84980009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000908A MX2024000908A (es) 2021-07-21 2022-07-20 Metodo para producir derivado de arilamida.

Country Status (12)

Country Link
US (1) US20240327355A1 (https=)
EP (1) EP4375273A4 (https=)
JP (2) JP7268255B1 (https=)
KR (1) KR102671612B1 (https=)
CN (1) CN117677607A (https=)
AR (1) AR126517A1 (https=)
AU (1) AU2022312992A1 (https=)
CA (1) CA3226827A1 (https=)
IL (1) IL310123A (https=)
MX (1) MX2024000908A (https=)
TW (1) TW202321198A (https=)
WO (1) WO2023003014A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007811A1 (zh) * 2023-07-06 2025-01-09 成都华健未来科技有限公司 一类芳香酰胺类衍生物及其用途
CN121866244A (zh) 2023-09-21 2026-04-14 中外制药株式会社 用于生产芳基酰胺衍生物的方法
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来(成都)科技股份有限公司 芳香酰肼类衍生物及其医药用途
CN118604164B (zh) * 2024-05-15 2025-06-06 石家庄四药有限公司 一种非奈利酮中间体中杂质的检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200520745A (en) * 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
PL2344474T3 (pl) * 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
AU2010317167B2 (en) * 2009-11-04 2012-11-29 Novartis Ag Heterocyclic sulfonamide derivatives useful as MEK inhibitors
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 5−置換−2−フェニルアミノ−ベンズアミド類の製造方法
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
AU2021311665A1 (en) * 2020-07-22 2023-03-16 Chugai Seiyaku Kabushiki Kaisha Composition containing arylamide derivative
JPWO2022018875A1 (https=) * 2020-07-22 2022-01-27

Also Published As

Publication number Publication date
AU2022312992A1 (en) 2024-02-29
CA3226827A1 (en) 2023-01-26
JPWO2023003014A1 (https=) 2023-01-26
JP7268255B1 (ja) 2023-05-02
AR126517A1 (es) 2023-10-18
WO2023003014A1 (ja) 2023-01-26
CN117677607A (zh) 2024-03-08
KR102671612B1 (ko) 2024-05-31
EP4375273A1 (en) 2024-05-29
JP2023084138A (ja) 2023-06-16
EP4375273A4 (en) 2025-05-21
IL310123A (en) 2024-03-01
TW202321198A (zh) 2023-06-01
KR20230152797A (ko) 2023-11-03
US20240327355A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
MX2024000908A (es) Metodo para producir derivado de arilamida.
CL2023000199A1 (es) Composición que contiene un derivado de arilamida
CL2021000737A1 (es) Fabricación de compuestos y composiciones para inhibir la actividad de shp2
CR20220559A (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
CU24735B1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CL2021002234A1 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
ECSP088830A (es) Compuestos de benzoxazole y benzotiazole sustituidos-6-o y métodos para inhibir la señalización csf-1r
MX2018006966A (es) Medicamento para tratar influenza caracterizado porque comprende una combinacion de un inhibidor de endonucleasa dependiente de casquete con un farmaco anti-influenza.
MX386930B (es) Análogos de canabidiol biológicamente activos.
CY1112237T1 (el) Παραγωγα 5-υδροξυ-βενζοθειαζολης που εχουν ενεργοτητα αγωνιστη βητα-2-αδρενοϋποδοχεα
MX2021012750A (es) Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
MX2019010324A (es) Método para preparar poli(carbonatos de éter).
NZ602710A (en) Use of novel pan-cdk inhibitors for treating tumors
RU2019127038A (ru) N1-(4-(5-(циклопропилметил)-1-метил-1h-пиразол-4-ил)пиридин-2-ил)циклогексан-1,4-диаминовые производные и родственные соединения в качестве ингибиторов сk1 и/или irak1 для лечения рака
RU2004136989A (ru) Цианогуанидиновые пролекарства
CO2022015976A2 (es) Síntesis de intermedios de vinil ciclobutilo
BR112023018246A2 (pt) Formas de sal e sólidas de um inibidor de cinase
BR112020020549A8 (pt) Novo processo para síntese de um composto fenoxi diaminopirimidina
ES2421605T3 (es) Inhibidores de trastorno isquémico o enfermedades
AR052301A1 (es) Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas
ES2523590T3 (es) Procedimiento de producción de aminas terciarias
MX2023013128A (es) Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
AR093257A1 (es) Compuestos insecticidas
BR112023002694A2 (pt) Processo para a preparação de derivados de piridazina quaternizada
MY207929A (en) Process for synthesis of a 2-(5-isoxazolyl)-phenol